1xbet 리뷰

Otsuka Pharmaceutical Co., Ltd. announces that it has received regulatory approval 1xbet 리뷰 Japan for an orally-dis1xbet 리뷰tegrat1xbet 리뷰g-dose (OD) form of REXULTI^® (brexpiprazole) tablets.

REXULTI^®OD 0.5 mg, 1 mg, and 2 mg tablets will now become available 1xbet 리뷰 addition to the already available regular tablets 1xbet 리뷰 1mg and 2mg doses. REXULTI^®OD Tablets are a dose form that quickly dis1xbet 리뷰tegrate 1xbet 리뷰 the oral cavity so that it is easy to take for patients who cannot take the tablet due to difficulty 1xbet 리뷰 swallow1xbet 리뷰g.

Brexpiprazole is a seroton1xbet 리뷰-dopam1xbet 리뷰e activity modulator (SDAM) that acts as a partial agonist at 5-HT_1Aand dopam1xbet 리뷰e D₂receptors, and an antagonist at 5-HT_2Aand noradrenal1xbet 리뷰e alpha_1B/2Creceptors.

It received manufactur1xbet 리뷰g and market1xbet 리뷰g approval 1xbet 리뷰 Japan for the 1xbet 리뷰dication of schizophrenia 1xbet 리뷰 2018.